BIIB Biogen Inc.

Biogen to Present at the 25th Annual Credit Suisse Healthcare Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--

Biogen Inc. (NASDAQ: BIIB) announced today that it will present at the 25th Annual Credit Suisse Healthcare Conference. The webcast will be live on Monday, November 7, 2016 at 9:00a.m. MT, 11:00a.m. ET. To access the live webcast, please visit Biogen’s Investors section at www.biogen.com/investors. An archived version of the webcast will be available for 14 days following the presentation.

About Biogen

Through cutting-edge science and medicine, Biogen discovers, develops and delivers worldwide innovative therapies for people living with serious neurological, autoimmune and rare diseases. Founded in 1978, Biogen is one of the world’s oldest independent biotechnology companies and patients worldwide benefit from its leading multiple sclerosis and innovative hemophilia therapies. For more information, please visit www.biogen.com. Follow us on Twitter.

EN
27/10/2016

Underlying

BIIBBiogen Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Biogen Inc.

 PRESS RELEASE
Free
BIIB BIOGEN INC.

The Journal of the American Medical Association (JAMA) Neurology Publi...

The Journal of the American Medical Association (JAMA) Neurology Publishes Long Term Results from the QALSODY Phase 3 VALOR Study and its Open-Label Extension in SOD1-ALS Long-term data published in JAMA Neurology further illustrate the effects of Biogen’s QALSODY on function, strength, and survival in SOD1-ALSOver 3 years, a subset of QALSODY-treated participants regained previously lost function and strength, something not previously reported in the natural history of SOD1-ALSBiogen is committed to advancing additional ALS research, including the ongoing QALSODY ATLAS study in pre-symptom...

December 22, 2025 1 EN
Laura Chico ... (+2)
  • Laura Chico
  • Thomas Yip
XENE XENON PHARMACEUTICALS INC
NBIX NEUROCRINE BIOSCIENCES INC.
BIIB BIOGEN INC.
ARDX ARDELYX INC
STOK STOKE THERAPEUTICS
EWTX EDGEWISE THERAPEUTICS INC
12/19/25 December 19, 2025 1 EN
Wedbush Research
  • Wedbush Research
XENE XENON PHARMACEUTICALS INC
NBIX NEUROCRINE BIOSCIENCES INC.
BIIB BIOGEN INC.
BCRX BIOCRYST PHARMACEUTICALS INC.
ARDX ARDELYX INC
WVE WAVE LIFE SCIENCES
FMCC FEDERAL HOME LOAN MORTGAGE CORPORATION
STOK STOKE THERAPEUTICS
EWTX EDGEWISE THERAPEUTICS INC
NATL NCR ATLEOS CORPORATION
DBD DIEBOLD NIXDORF INCORPORATED
12/12/25 December 12, 2025 1 EN
Laura Chico ... (+2)
  • Laura Chico
  • Thomas Yip
XENE XENON PHARMACEUTICALS INC
NBIX NEUROCRINE BIOSCIENCES INC.
BIIB BIOGEN INC.
ARDX ARDELYX INC
STOK STOKE THERAPEUTICS
EWTX EDGEWISE THERAPEUTICS INC
12/12/25 December 12, 2025 1 EN
 PRESS RELEASE
Free
BIIB BIOGEN INC.

Biogen and Stoke Therapeutics Present Data that Further Support the Di...

Biogen and Stoke Therapeutics Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting —Long-term Phase 1/2a and open label extension (OLE) data for zorevunersen on top of standard of care anti-seizure medicines (ASMs) demonstrate durable seizure reductions, including increases in seizure-free days, in addition to improvements in cognition, behavior and quality of life— —Propensity score weighted analysis comparing the effects of zorevunerse...

December 5, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch